Brodalumab a Successful, Safe Treatment Option for Nail Psoriasis
The efficacy of brodalumab for the treatment of nail psoriasis is assessed.
Plaque Psoriasis
Psoriasis Flare Rates Low in Patients Receiving Systemic Corticosteroids
Do steroids induce severe psoriasis flares at significant rates in a general psoriasis population?
Tildrakizumab Prevents Relapse for Patients With Interrupted Psoriasis Treatment
Time to, and predictors of, relapse in patients with psoriasis who responded to tildrakizumab then were assigned to placebo were reported.
Secukinumab Associated With Greater PASI 2 or Lower Achievement vs Ustekinumab in Psoriasis
The effectiveness of ustekinumab and secukinumab in the treatment of psoriasis was assessed.
Low and High Doses of Secukinumab Prove Effective, Safe to 1 Year in Children With Chronic Plaque Psoriasis
The efficacay and safety of 2 secukinumab dosing regimens in a pediatric population with severe chronic plaque psoriasis were evaluated.
Treatment of Psoriasis With IBD May Require Higher Doses of Risankizumab
A case report of a man with plaque psoriasis and comorbidities that include psoriatic arthritis and ulcerative colitis.
Ustekinumab Efficacious for Children With Moderate to Severe Psoriasis
Early efforts to characterize the efficacy of treatment of psoriasis with ustekinumab in pediatric patients are reviewed.
Psoriasis Treatment and VCAM-1, E-Selectin Levels May Affect Risk for Cardiovascular Disease
VCAM-1 and E-selectin levels and their relationship with psoriasis severity were evaluated.
Deucravacitinib Shows Superiority to Apremilast in Psoriasis Trial
A phase 3 trial evaluating the efficacy and safety of deucravacitinib (BMS-986165; Bristol Myers Squibb), a novel, oral, selective TYK2 inhibitor, for the treatment of patients with moderate to severe plaque psoriasis met both co-primary and secondary end points.
Topical Foam May Extend Remission From Plaque Psoriasis
Long-term efficacy and safety of proactive psoriasis management
with twice-weekly calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam for plaque psoriasis was assessed in a novel trial.
-
Loading...
-
Loading...
Next post in Psoriasis
